

PROVIDER Update



CONTRACTUAL | AUGUST 2, 2024 | UPDATE 24-784 | 4 PAGES

New: 2nd Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after October 7, 2024

On April 9, 2024, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. P&T Committee members include physicians and representatives from participating physician groups (PPGs).

The approved updates, effective October 7, 2024, are listed on pages 2-4 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* *Provider Participation Agreement (PPA)*.

The update includes:

- 12 new injectable medications to be added to the DOFR crosswalk.
- 11 updates and changes to injectable medication procedure codes.
- 6 updated categories.
- 3 updates for new generic drugs.

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at provider.healthnetcalifornia.com > *Provider Library under Quick Links*, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer/Group
 - HMO/POS
 - PPO
- Wellcare By Health Net
 - Medicare Advantage (HMO)
 - Medicare Advantage (PPO)
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP
Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP
Ambetter PPO – 844-463-8188

Health Net Employer Group
HMO, POS & PPO 800-641-7761

Medicare (individual & employer group)
(Wellcare By Health Net) – 800-929-9224

Medi-Cal (including CS and ECM providers)
– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Amtagvi™	Lifileucel IV suspension 72,000,000,000 cells	Therapeutic injection	
J3590	Cosentyx® IV	Secukinumab IV solution 125 mg/5 mL	Therapeutic injection	
J3590	Cosentyx® Unoready®	Secukinumab subcutaneous solution auto-injector 300 mg/2 mL	Self-injectable	Chemotherapy adjunctive ¹
J1323	Elrexio™	Injection, elranatamab-bcmm, 1 mg	Therapeutic injection	Blood/blood products for hemophilia
Q5111	Udenyca Onbody™	Pegfilgrastim-cbqv on-body injector	Therapeutic injection	
90623	Penbraya™	Meningococcal ACWY (Tet Conj)-Mening B (Rcmb) vaccines for injection	Therapeutic injection	
J3490	Rivfloza™	Nedosiran sodium subcutaneous solution 80 mg/0.5 mL	Self-injectable	
Q5133	Tofidence™	Tocilizumab-bavi, biosimilar, 1 mg	Therapeutic injection	
Q5134	Tyruko®	Injection, natalizumab-sztn, biosimilar, 1 mg	Therapeutic injection	
J3490	Wainua™	Eplontersen sodium subcutaneous solution auto-injector 45 mg/0.8 mL	Self-injectable	
J3490	Zilbrysq®	Zilucoplan sodium subcutaneous solution prefilled syringe 16.6 mg/0.416 mL	Self-injectable	
J3590	Zymfentra®	Infliximab-dyyb) injection for subcutaneous use from Celltrion USA	Self-injectable	

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J9321	Epkinly™	Epcoritamab-bysp injection, for subcutaneous (SC) use	Replaces C9155
J0172	Aduhelm™	Aducanumab-avwa IV solution	No longer manufactured
J1412	Balfaxar®	Injection, prothrombin complex concentrate (human), per IU of Factor IX activity	Replaces C9159
J0177	Eylea® hd	Aflibercept Injection 8 mg	Replaces J3490
J2277	Aphexda™	Motixafortide acetate, for subcutaneous injection 62 mg	Replaces J3490
J0589	Daxxify®	DaxibotulinumtoxinA-lanm, for injection and intramuscular use	Replaces C9160
J3055	Talvey™	Talquetamab-tgvs injection, for subcutaneous use	Replaces J9999
J9376	Veopoz™	Pozelimab-bbfg injection solution	Replaces J3590
J2801	Rykindo®	Risperidone, for extended-release injectable suspension and intramuscular use	Replaces J2794
J2782	Izervay™	Avacincaptad pegol intravitreal solution 2 mg/0.1 mL (20 mg/mL)	Replaces C9162
J3490	Reditrex®	Methotrexate injection, for subcutaneous use	No longer manufactured

Category changes

The following medications have been approved to correct the secondary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9260	Methotrexate	Methotrexate powder 1 gm in 50 mL sodium vial (p.f.), methotrexate sodium injection, 25 mg/mL	Therapeutic injection	Chemotherapy ¹
J9260	Methotrexate	Methotrexate powder 1 gm in 50 mL sodium vial (p.f.), methotrexate sodium injection, 25 mg/mL (not for chemotherapy)	Self-injectable	
J3590	Adbry™	Tralokinumab-ldrm injection, for subcutaneous use	Self-injectable	
J0219	Nexviazyme™	Avalglucosidase alfa-ngpt	Therapeutic injection	Home health/infusion ²
J3397	Mepsevii™	Vestronidase alpha-vjbk	Therapeutic injection	Home health/infusion ²
J0218	Xenpozyme™	Injection, olipudase alfa-rpcp, 1 mg	Therapeutic injection	Home health/infusion ²

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J1434	Focinvez™	Injection, fosaprepitant, 1 mg	Therapeutic injection	Chemotherapy adjunctive ¹
J9249	Melphalan hydrochloride injection	Injection, melphalan (apotex), 1 mg	Therapeutic injection	Chemotherapy ¹
J9074	Cyclophosphamide injection	Injection, cyclophosphamide (sandoz), 5 mg	Therapeutic injection	Chemotherapy ¹

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.